跳至主要内容
临床试验/NL-OMON38858
NL-OMON38858已完成不适用

A randomized, double blind, placebo-controlled crossover study to investigate the effects of a selective serotonergic reuptake inhibitor on resting state fMRI in heathy volunteers. - Pharmacological resting state fMRI with an SSRI.

Centre for Human Drug Research0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Have a body-mass index (BMI) between 18 and 30 kg/m2.
  • Each subject is familiar with the procedures of the study, and agrees to participate in the study program by giving oral and written informed consent.
  • Age subjects: age 18-30.

排除标准

  • Contra-indication to MRI scanning (pacemaker and defibrillator, intraorbital or intraocular metallic fragments, cochlear implants, one or more metal eartubes, intracranial clips, a non-removable insulin pump, a non-removable neurostimulator, a mechanical cardiac valve, an hydrocephalus pump, ferromagnetic implants, intra-uterine device, permanent make-up, tattoos above the shoulders, pregnancy, operation in 6 weeks preceding the MRI, claustrophobia, inability to lie still for a period of 20 minutes in the MRI scanner, Fear or problems during the RS-FMRI scan).
  • Relatives of study personnel directly involved with the conduct of the study, study investigators or sub-investigators.
  • Clinically relevant abnormal history of physical and mental health as determined by medical history taking and physical examinations obtained during the screening visit (as judged by the investigator).
  • Clinically relevant abnormal laboratory results, ECG and vital signs, or physical findings at screening (as judged by the investigator).
  • Positive test for hepatitis B, C or HIV.
  • Subjects using, on average, more than 4 units of alcohol per day, and unable to refrain from alcohol use during the study days.
  • Subjects smoking, on average, more than 5 cigarettes per day, and unable to refrain from smoking during the study days.
  • Subject is a habitual and heavy consumer of caffeinated beverages (more than 6 cups of coffee or equivalent/day) at the time of the study and/or is not able to refrain from use of (methyl) xanthines (e.g. coffee, black tea, cola, chocolate) during study days.
  • Positive drug or alcohol test at screening and/or study days.
  • History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the study drug.
  • Participation in an investigational drug trial in the 3 months prior to administration of the initial dose of study drug or more than 4 times per year.
  • Donation or loss of blood (> 500 mL) within 3 months prior to screening.
  • Inadequate venous accessibility as judged by the physician or nurse.
  • Use of benzodiazepine within 48 hours before a study day.
  • Pregnancy or breast feeding.
  • Any other condition that in the opinion of the investigator would complicate or compromise the study, or the well being of the subject.
  • Use of medication in the 2 weeks prior to the first study day that is, in the opinion of the investigator, interfering with the study or the study medication.

研究者

相似试验